Path towards efficient paediatric formulation development based on partnering with clinical pharmacologists and clinicians, a conect4children expert group white paper

Walsh, Jennifer and Schaufelberger, Daniel and Iurian, Sonia and Klein, Sandra and Batchelor, Hannah and Turner, Roy and Gizurarson, Sveinbjörn and Boltri, Luigi and Alessandrini, Elisa and Tuleu, Catherine (2021) Path towards efficient paediatric formulation development based on partnering with clinical pharmacologists and clinicians, a conect4children expert group white paper. British Journal of Clinical Pharmacology, 88 (12). pp. 5034-5051. ISSN 0306-5251 (https://doi.org/10.1111/bcp.14989)

[thumbnail of Walsh-etal-BJCP-2021-Path-towards-efficient-paediatric-formulation-development-based-on-partnering-with-clinical-pharmacologists]
Preview
 Text. Filename: Walsh_etal_BJCP_2021_Path_towards_efficient_paediatric_formulation_development_based_on_partnering_with_clinical_pharmacologists.pdf
Accepted Author Manuscript
Download (977kB)| Preview

Abstract

Improved global access to novel age-appropriate formulations for paediatric subsets, either of new chemical entities or existing drugs, is a priority to ensure that medicines meet the needs of these patients. However, despite regulatory incentives, the introduction to the market of paediatric formulations still lags behind adult products. This is mainly caused by additional complexities associated with the development of acceptable age-appropriate paediatric medicines. This position paper recommends the use of a paediatric Quality Target Product Profile as an efficient tool to facilitate early planning and decision making across all teams involved in paediatric formulation development during the children-centric formulation design for new chemical entities, or to repurpose/reformulate off-patent drugs. Essential key attributes of a paediatric formulation are suggested and described. Moreover, greater collaboration between formulation experts and clinical colleagues, including healthcare professionals, is advocated to lead to safe and effective, age-appropriate medicinal products. Acceptability testing should be a secondary endpoint in paediatric clinical trials to ensure postmarketing adherence is not compromised by a lack of acceptability. Not knowing the indications and the related age groups and potential dosing regimens early enough is still a major hurdle for efficient paediatric formulation development; however, the proposed paediatric Quality Target Product Profile could be a valuable collaborative tool for planning and decision making to expedite paediatric product development, particularly for those with limited experience in developing a paediatric product.

ORCID iDs

Walsh, Jennifer, Schaufelberger, Daniel, Iurian, Sonia, Klein, Sandra, Batchelor, Hannah ORCID logoORCID: https://orcid.org/0000-0002-8729-9951, Turner, Roy, Gizurarson, Sveinbjörn, Boltri, Luigi, Alessandrini, Elisa and Tuleu, Catherine;
CORE (COnnecting REpositories)